This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Cell Based Assays Remove Cell Biology Remove Disease Remove Doctors
article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

APRIL 29, 2024

Inspired by her time at GSK, Millie pursued a PhD at the University of Cambridge investigating the signalling pathways that drive cancer cell growth using in-vitro cell based assays and biochemical analysis. Driven by an interest in drug discovery Millie joined AstraZeneca after completion of her PhD at the end of 2020.

Bioinformatics 59
Bioinformatics Molecular Biology Drugs Cell Based Assays 59
article thumbnail

Flow cytometry technologies and cancer associated fibroblasts

Drug Discovery World

OCTOBER 20, 2022

Inside any solid tumour there is high heterogeneity, and the types of tumour cells, immune cells, and stromal cells present and their functional states dictate disease severity and progression. Instead, fibroblasts are frequently identified using a combination of positive and negative markers along with cell morphology.

Cell Based Assays 130
Cell Based Assays Therapies Cell Biology RNA 130
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 15,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024